Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00427687 · ClinicalTrials.gov registry record · Phase 1
Study Evaluating AGG-523 in Subjects With Osteoarthritis
A Phase 1 study, sponsored by Wyeth is now a wholly owned subsidiary of Pfizer.
- Completed
- Registry status
- Phase 1
- Development phase
NCT00427687: Completed Phase 1 study, sponsored by Wyeth is now a wholly owned subsidiary of Pfizer.
NCT00427687 is a Phase 1 study that has completed, run by Wyeth is now a wholly owned subsidiary of Pfizer. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00427687, a Phase 1 study, has completed, sponsored by Wyeth is now a wholly owned subsidiary of Pfizer.
- COMPLETED
- Registry status
- Phase 1
- Development phase
Study Summary
This study will evaluate the effect of AGG-523 administration on biomarkers related to osteoarthritis. Safety and tolerability of AGG-523 will also be assessed.
Interventions
- DRUG AGG-523
Trial Details
| Field | Value |
|---|---|
| Start Date | 2007-02 |
| Est. Completion | 2007-06 |
| Phase | Phase 1 |
What the finished NCT00427687 record still lists
NCT00427687 is an interventional study that assigns participants to a tested intervention. An enrollment target was not published in the registry record, which is common for early-stage or observational entries.
The record links to 0 conditions, and to 1 intervention - of which AGG-523 is the first listed.
NCT00427687 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00427687 about?
NCT00427687 is a clinical study titled "Study Evaluating AGG-523 in Subjects With Osteoarthritis". This study will evaluate the effect of AGG-523 administration on biomarkers related to osteoarthritis. Safety and tolerability of AGG-523 will also be assessed.
What is the current status of trial NCT00427687?
This trial is currently completed. It is a Phase 1 study. The study started on 2007-02. Estimated completion is 2007-06.
What interventions are being tested in trial NCT00427687?
The interventions under investigation include: AGG-523 (DRUG).
Who is sponsoring clinical trial NCT00427687?
This trial is sponsored by Wyeth is now a wholly owned subsidiary of Pfizer, which has 167 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia